|By Marketwired .||
|September 24, 2013 09:35 AM EDT||
MEDFORD, MA--(Marketwired - September 24, 2013) - Hepregen Corporation, leader in the development of next generation HepatoPac™ and HepatoMune™ cell-based assay products, announced today the commercial launch of the Company's first application-oriented, dual-species HepatoPac™ kit designed specifically for use in metabolite identification and profiling. Each kit contains one standard 24-well tissue culture plate, half containing micro-patterned human hepatocytes, and the other half containing micro-patterned rat hepatocytes (available in Wistar-Hahn or Sprague-Dawley strains). The hepatocytes on these plates from both species remain fully functional for up to two months. These unique dual-species kits provide customers with a plug-in-ready product, designed for use in evaluating metabolite production in a discovery or development setting, or in any case where a quick comparative answer is beneficial.
Dr. Vincent Zurawski, Hepregen's chief executive officer stated, "The incredible flexibility of our HepatoPac™ assay systems allows Hepregen to provide customers with a variety of cost-effective options for generating predictive and mechanistic data regarding metabolite identification and profiling." He added, "The launch of this new dual-species product represents another way in which Hepregen is responding to customer needs. Data collected from two species simultaneously in a single experiment, especially when one or just a few compounds need to be evaluated rapidly, provides the highest efficiency approach to predicting likely in vivo metabolic outcomes in the laboratory."
Jack McGeehan, Hepregen's vice president of operations, added, "Our new dual-species product is a perfect fit for both smaller pharmaceutical companies that are testing a limited number of compounds, or DMPK groups within larger companies who support program teams in need of quick answers to questions regarding likely best approaches to preclinical evaluation. Our new HepatoPac™ kit can provide answers that will support clinical trial design or approaches to toxicokinetic testing."
About Hepregen Corporation
Hepregen Corporation is the undisputed leader in innovating unique and proprietary bioengineered micro-liver platforms for use in environmental testing, preventive care, and pharmaceutical, biotherapeutic and diagnostic product development. The Company's micro-liver HepatoPac™ and HepatoMune™ cell-based assay are driving a paradigm shift in drug development. The utility of Hepregen's human, rat, monkey and dog HepatoPac™ and HepatoMune™ products has been validated in collaboration with investigators at several well-known pharmaceutical companies. Additionally, new applications for these products are being tested by Hepregen, its pharmaceutical company customers, and its academic and business partners. Hepregen was founded and capitalized by Battelle Ventures with technology licensed from the Massachusetts Institute of Technology. The technology was developed by Professor Sangeeta Bhatia, who is a world renowned expert and leader in liver bioengineering for life science and therapeutic applications.